Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | RAMPART: quality of life with adjuvant durvalumab in renal cell carcinoma

Sophie Merrick, MBCHB, MRCP, University College London, London, UK, discusses patient-reported quality-of-life outcomes from the RAMPART (NCT03288532) trial of one year of adjuvant durvalumab versus active monitoring in patients with resected intermediate- or high-risk renal cell carcinoma. Durvalumab was associated with small but clinically meaningful early worsening of overall quality of life, role and cognitive function, fatigue, and appetite loss. While overall quality of life and role function recovered over time, cognitive, fatigue, and appetite effects persisted, with later changes in dyspnea and constipation warranting cautious interpretation. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So RAMPART is an investigator-led phase 3 trial in participants with resected renal cell carcinoma at intermediate or high risk of recurrence and in some selected patients with resected metastatic disease. And participants were randomised in a 3 to 2 to 2 ratio to either active monitoring, atezolizumab monotherapy for one year, or durvalumab for a year with tremelimumab at day one and week four...

So RAMPART is an investigator-led phase 3 trial in participants with resected renal cell carcinoma at intermediate or high risk of recurrence and in some selected patients with resected metastatic disease. And participants were randomised in a 3 to 2 to 2 ratio to either active monitoring, atezolizumab monotherapy for one year, or durvalumab for a year with tremelimumab at day one and week four. So Rampart’s previously reported its efficacy results, which showed that durvalumab and tremelimumab demonstrated a disease-free survival benefit, whereas atezolizumab monotherapy did not. When we look at the safety between the three, there were higher rates of grade four adverse events with the combination of atezolizumab and tremelimumab and then with durvalumab compared to active monitoring. But interestingly, when we looked at our primary quality of life outcome, they showed no evidence of a difference between arms. So today we are presenting patient reported outcomes, more detailed patient reported outcomes beyond that primary quality of life endpoint. And what we’ve shown is despite no difference in that primary outcome, a number of functional domains and symptom and item subscales were worse with durvalumab monotherapy than with active monitoring, so that that primary quality of life endpoint wasn’t fully capturing the patient experience.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.